Publications by authors named "Ralph Biemans"
7vCRM (Pfizer, Inc.) and PHiD-CV (GlaxoSmithKline Biologicals) are two pneumococcal conjugate vaccines licensed for the prevention of invasive pneumococcal disease and acute otitis media caused by the vaccine serotypes of Streptococcus pneumoniae. Neither vaccine contains serotype 19A, but both contain the closely related serotype 19F.
View Article and Find Full Text PDFArticle Synopsis
- Nicotine replacement therapies (NRT) aren't very effective for quitting smoking, partly due to the effects of cotinine, a metabolite of nicotine that interferes with its action.
- Research shows that cotinine acts as a weak agonist, which can reduce the effectiveness of nicotine by desensitizing receptors in the body.
- An experimental anti-cotinine vaccine was developed, leading to the production of antibodies that specifically target cotinine, which might help improve smoking cessation efforts by preventing cotinine from hindering nicotine's effects.